全球 EZH2 標靶治療市場：市場機會、已核准藥物定價、銷售及臨床試驗展望（至 2026 年）

全球 EZH2 標靶治療市場 - 市場機會、已核准藥物定價、銷售及臨床試驗展望（至 2026 年）研究結果及亮點：

• 全球及區域市場趨勢分析
• 已核准的 EZH2 標靶治療藥物數量：2
• EZH2 標靶治療藥物有條件核准數量：1
• 已核准藥物的劑量、價格及銷售情況分析
• 按公司、國家、適應症及階段劃分的全球 EZH2 標靶治療臨床試驗分析
• 主要標靶治療藥物的啟動及完成年份分析
• 競爭格局

EZH2 標靶治療的需求治療方法及本報告的意義

抑制 EZH2（增強子 Zeste 同源物 2）是現代治療的前沿，尤其是在血液腫瘤和實體瘤的治療中。近年來，作為多梳抑制複合物 2 (PRC2) 的關鍵催化亞基，EZH2 的抑制已成為現代癌症治療的主要標靶之一。 EZH2 抑制對錶觀遺傳修飾具有重要意義，特別是組蛋白 H3 第 27 位殘基（稱為 H3K27me3）的修飾，可抑制參與細胞分化、增殖或腫瘤抑制的基因表現。 EZH2 的異常活性，例如過度表現、突變或 PRC2 訊號傳導異常，與包括實體瘤在內的多種白血病的發生髮展密切相關。因此，EZH2 已成為開發針對這些惡性腫瘤的潛在療法的極具吸引力且經過生物學驗證的標靶。本報告全面而深入地概述了EZH2標靶治療策略的現狀，涵蓋了從小分子抑制劑到新一代表觀遺傳療法和聯合療法等各個方面，可謂恰逢其時，意義重大。

本報告概述了目前的臨床現狀、技術發展、關鍵參與者和策略聯盟，這些都表明EZH2抑制療法是腫瘤學領域的下一個重大突破。報告強調了EZH2標靶療法日益增長的重要性，並深入分析了其在革新癌症治療方面的潛力，尤其針對那些存在EZH2失調或突變的癌症。隨著創新加速發展，本報告是追蹤未來幾年將影響癌症治療的最新進展的重要指南。

本報告涵蓋的EZH2標靶療法臨床試驗概況

本報告分析了EZH2標靶療法的最新臨床試驗，並詳細介紹了處於不同階段的正在進行的試驗。本報告探討了這些試驗的現狀以及正在進行的試驗中令人鼓舞的結果。臨床活性已在多種癌症適應症中得到驗證，包括濾泡性淋巴瘤、上皮樣肉瘤、週邊T細胞淋巴瘤和轉移性前列腺癌。

本報告檢視了多種EZH2抑制劑的療效和安全性，包括Tazberic（tazemetostat）、zemetostat和mebrometostat，並在條件允許的情況下概述了患者的緩解率、無惡化存活期和總生存期結果。此外，本報告也指出了具有協同增效作用的治療方案，例如將EZH2抑制劑與免疫檢查點抑制劑和傳統化療藥物合併使用的療法。基於臨床試驗結果，本報告強調了EZH2抑製作為治療方法的巨大潛力，並重點指出了未來最值得關注的創新領域。

積極參與 EZH2 標靶療法研發的關鍵公司

多家大型公司正在推動 EZH2 標靶療法的研發。本報告重點介紹並列出了積極從事 EZH2 標靶藥物研發的關鍵公司。 Tazberic 的生產商 Epizyme（現為 Ipsen）是該領域的先驅，並持續擴大針對多種癌症類型的臨床試驗。其他公司，例如恆瑞製藥的 zemetostat 和輝瑞的 mebrometostat，也在開髮用於治療血液腫瘤和實體瘤的 EZH2 抑制劑方面取得了穩步進展。

本報告也探討了新興生技公司的研究趨勢。例如，Treeline Biosciences 正在探索 EZH2 抑制的新作用機制，而韓美製藥正在開發雙重 EZH1/2 抑制劑 HM97662。這些公司正在探索多種方法，包括靶向 EZH2 的非酶活性以及開發選擇性降解劑，以克服抗藥性並提高 EZH2 抑制劑的治療效果。本報告提供了全面的公司概況、旗艦專案和臨床研究方法，為利害關係人提供了重要的見解。

一份重點介紹 EZH2 標靶療法未來發展的報告

EZH2 標靶療法的前景非常光明。本報告詳細介紹了該領域的預期發展，包括針對各種癌症類型正在進行的 EZH2 抑制劑臨床研究。隨著更多生物標記得到驗證並納入臨床決策，治療將越來越個人化，從而改善患者的獲益風險比。未來 EZH2 標靶療法預計將涉及抑制劑、促進降解劑和其他旨在克服抗藥性的新型策略的聯合應用。

此外，新一代藥物的出現，例如雙重 EZH1/EZH2 抑制劑和選擇性 EZH2 降解劑，有望提供更精準有效的治療。本報告預測，策略聯盟和合作關係的重要性將持續提升，推動創新並加速新型療法的上市。隨著技術的進步和新型藥物研發管線的不斷擴充，EZH2 抑制劑有望成為腫瘤治療方案的重要組成部分，為患有難治性癌症的患者帶來新的希望。

目錄

第一章：EZH2標靶治療簡介

• EZH2標靶治療概述
• 發展與演變

第二章：EZH2機制解析與治療標靶

• 小分子抑制劑
  • 催化抑制劑
  • 變構抑制劑
• EZH2降解劑
• 基因沉默

第三章：EZH2標靶治療臨床試驗的全球概覽

• 依階段
• 依國家/地區
• 按公司
• 按適應症

第四章：Tazveric－首個核准的 EZH2 標靶治療藥物

• 概述、上市狀況及專利信息
• 劑量及定價分析
• 銷售分析

第五章：Ezharmi－第二個核准的 EZH2 標靶治療藥物

第六章：Zepulmetostat（有條件批准，2025 年 9 月）

第七章：全球 EZH2 標靶治療藥物市場分析

• 當前市場狀況
• 未來市場機遇

第八章：EZH2 標靶治療藥物市場機會（按地區劃分）

• 美國國家/地區
• 歐洲
• 日本
• 中國
• 韓國

第九章 EZH2 的作用及標靶治療發展趨勢（依適應症劃分）

• 癌症
  • 實體瘤
  • 血液系統惡性腫瘤
• 自體免疫疾病與發炎性疾病
• 神經系統疾病
• 其他

第十章 EZH2 標靶治療臨床試驗的全球概況（按公司、國家、適應症和階段劃分）

• 臨床前
• I 期
• I/II 期
• III 期
• 已註冊

第十一章 EZH2 的商業化臨床試驗標靶治療：按公司、國家、適應症和階段劃分

第十二章 全球 EZH2 標靶治療市場動態

• 市場驅動因素與機遇
• 挑戰與策略解決方案

第十三章 競爭格局

• Axter Therapeutics
• Daiichi Sankyo
• Evopoint Biosciences
• GSK
• Haihe Biopharma
• Hanmi Pharmaceutical
• Ipsen
• Jiangsu HengRui Medicine.
• Novartis
• Pfizer

Global EZH2 Targeted Therapy Market Opportunity, Approved Drug Price, Sales & Clinical Trials Insight 2026 Report Findings & Highlights:

• Global & Regional Market Trends Insight
• Number Of Approved EZH2 Targeted Therapies: 2 Therapies
• Conditional Approval To EZH2 Therapy: 1 Therapy
• Approved Therapy Dosage, Price & Sales Insight
• Global EZH2 Targeted Therapy Clinical Trials Insight By Company, Country, Indication & Phase
• Key Therapies Initiation & Completion Year Insight
• Competitive Landscape

Need For EZH2 Targeting Therapies & Why This Report

Inhibition of EZH2 (Enhancer of Zeste Homolog 2) has been at the forefront of contemporary therapy, especially for hematologic cancers and solid tumors. Inhibition of EZH2, an important catalytic subunit of the Polycomb Repressive Complex 2 (PRC2), has recently become one of the primary areas being targeted in modern cancer treatment. Inhibiting EZH2 has significant implications in epigenetic modification, specifically in histone H3 at residue 27, known as H3K27me3, which represses gene expression involved in cell differentiation, proliferation, or suppressing tumors. Aberrant EZH2 activity, either via overexpression, mutation, or PRC2 signaling, has been extensively linked in the etiology of many different forms of leukemia, including solid cancers. Consequently, EZH2 has become an attractive, biologically proven target for developing potential medicines for these malignancies. The present report comes at a critical time and is greatly needed, as it presents a comprehensive and critical overview of current developments in EZH2 targeting strategies, ranging from small molecule inhibitors to next generation epigenetic and combination based approaches.

The report provides an overview of the present clinical landscape, technology developments, important players, and strategic collaborations that are making EZH2 inhibition in oncology the next big thing. It underscores the increasing significance of EZH2 targeted therapies, providing insights into how the treatments may revolutionize the treatment of cancers, especially those with dysregulation or mutations in EZH2. With innovation speeding up, this report is an essential guide to following developments that will likely influence cancer care over the next few years.

EZH2 Targeting Therapies Clinical Trials Insight Covered In Report

The report explores the most recent clinical trials of EZH2 Targeted therapies, providing in-depth insights into ongoing trials across various phases. It discusses not just the status of these trials as it stands now but also the encouraging outcomes coming from ongoing trials. Clinical activity is seen across a broad spectrum of cancer indications, such as follicular lymphoma, epithelioid sarcoma, peripheral T-cell lymphoma, and metastatic prostate cancer.

The report reviews the efficacy and safety profiles of different EZH2 inhibitors such as Tazverik (tazemetostat), Zemetostat, and Mevrometostat, giving an overview of patient response rates, progression free survival, and overall survival outcomes wherever possible. Moreover, the report identifies combination treatments, including those combining EZH2 inhibitors with immune checkpoint drugs or traditional chemotherapy drugs, with synergistic activities and increased therapeutic benefits. Based on clinical trial outcomes, the report identifies increasing optimism around EZH2 inhibition as a treatment approach as well as areas with the greatest potential for future innovations.

Leading Companies Active In R&D On EZH2 Targeting Therapies

Several key companies are driving the development of EZH2 targeting treatments forward. The report profiles and identifies the dominant players actively advancing EZH2 targeted drug development. Epizyme (Now Ipsen), the maker of Tazverik, is a trailblazer in the field and is continuing to grow its clinical trials in a variety of cancers. Other companies such as Hengrui Pharmaceuticals' Zemetostat and Pfizer's mevrometostat are also making good progress in developing EZH2 inhibitors for both hematologic and solid cancers.

The report also discusses the research of upcoming biotech companies such as Treeline Biosciences, which is exploring novel mechanisms of action for EZH2 inhibition, and Hanmi Pharmaceutical, which is developing the dual EZH1/2 inhibitor HM97662. These firms are pursuing varied approaches, such as targeting the non-enzymatic activities of EZH2 and developing selective degraders, to breach resistance and increase therapeutic effectiveness against EZH2 inhibition. The report offers comprehensive company profiles, lead programs, and clinical approaches, giving stakeholders important insights.

Report Indicating Future Development Of EZH2 Targeting Therapies

In the future, the prospects for EZH2 targeted therapies are very bright. The report details the anticipated course of the field, with sustained clinical investigation of EZH2 inhibitors in various cancers. The therapies will become progressively more personalized as more biomarkers are validated and incorporated into clinical decision making, enhancing the benefit risk profiles for patients. The future of EZH2 targeting is anticipated to involve a combination of inhibitors, degraders, and other new strategies designed to overcome resistance.

Besides, with the onset of next generation drugs such as dual EZH1/EZH2 inhibitors and selective EZH2 degraders, the area is set to provide more accurate and effective therapies. The report also predicts the growing significance of strategic collaborations and partnerships, which will keep on fueling innovation and taking new treatments to the market at a faster rate. As the technology advances and more new agents move into the pipeline, EZH2 inhibitors will become an important component of the oncology portfolio, bringing new hope to patients suffering with challenging and difficult to treat cancers.

Table of Contents

1. Introduction To EZH2 Targeted Therapies

• 1.1 Overview Of EZH2 Targeted Therapies
• 1.2 Development & Evolution

2. Mechanistic Insights & Therapeutic Targeting Of EZH2

• 2.1 Small Molecule Inhibitors
  • 2.1.1 Catalytic Inhibitors
  • 2.1.2 Allosteric inhibitors
• 2.2 EZH2 Degraders
• 2.3 Gene Silencing

3. Global EZH2 Targeted Therapy Clinical Trials Overview

• 3.1 By Phase
• 3.2 By Country
• 3.3 By Company
• 3.4 By Indication

4. Tazverik - First Approved EZH2 Targeted Therapy

• 4.1 Overview, Availability & Patent Insight
• 4.2 Dosage & Price Analysis
• 4.3 Sales Analysis

5. Ezharmi - Second Approved EZH2 Targeted Therapy

6. Zeprumetostat (Conditional Approval September 2025)

7. Global EZH2 Targeted Therapy Market Analysis

• 7.1 Current Market Scenario
• 7.2 Future Market Opportunities

8. Global EZH2 Targeted Therapy Market Opportunity By Region

• 8.1 US
• 8.2 Europe
• 8.3 Japan
• 8.4 China
• 8.5 South Korea

9. EZH2 Role & Targeted Therapy Development Trends By Indication

• 9.1 Cancer
  • 9.1.1 Solid Cancer
  • 9.1.2 Hematologic Malignancies
• 9.2 Autoimmune & Inflammatory Diseases
• 9.3 Neurological Disorders
• 9.4 Others

10. Global EZH2 Targeted Therapy Clinical Trials Insight By Company, Country, Indication & Phase

• 10.1 Preclinical
• 10.2 Phase I
• 10.3 Phase I/II
• 10.4 Phase III
• 10.5 Registered

11. Marketed EZH2 Targeting Therapy Clinical Trials Insight By Company, Country, Indication & Phase

12. Global EZH2 Targeted Therapy Market Dynamics

• 12.1 Market Drivers & Opportunities
• 12.2 Challenges & Strategic Solutions

13. Competitive Landscape

• 13.1 Axter Therapeutics
• 13.2 Daiichi Sankyo
• 13.3 Evopoint Biosciences
• 13.4 GSK
• 13.5 Haihe Biopharma
• 13.6 Hanmi Pharmaceutical
• 13.7 Ipsen
• 13.8 Jiangsu HengRui Medicine.
• 13.9 Novartis
• 13.10 Pfizer

List of Figures

• Figure 1-1: EZH2 - Functions & Relevance As Therapeutic Target
• Figure 1-2: Dual Biological Role Of EZH2
• Figure 1-3: EZH2 Inhibitors - Regulatory Milestones
• Figure 1-4: EZH2 Inhibition - Resistance Mechanisms
• Figure 1-5: Timeline Of EZH2 research & Drug Milestones
• Figure 2-1: EZH2 Inhibition - Mechanistic Overview
• Figure 2-2: Catalytic vs. Allosteric EZH2 Inhibition
• Figure 2-3: EZH2 Degraders - Mechanism Of Action
• Figure 2-4: EZH2 Degradation - Downstream Biological Consequences In Cancer
• Figure 2-5: EZH2 Degradation - Therapeutic Rationale
• Figure 2-6: Overview Of Gene Silencing Approaches Targeting EZH2
• Figure 2-7: EZH2 Gene Silencing - Advantages In Cancer Therapy
• Figure 3-1: Global - Number Of EZH2 Targeted Therapies In Clinical Trials By Phase, 2026
• Figure 3-2: Global - Number Of EZH2 Targeting Therapies In Clinical Trials By Country, 2026
• Figure 3-3: Global - Number Of EZH2 Targeting Therapies In Clinical Trials By Company, 2026
• Figure 3-4: Global - Number Of EZH2 Targeting Therapies In Clinical Trials By Indication, 2026
• Figure 4-1: Tazverik -Approval Year By Region
• Figure 4-2: Tazverik - Patent Filing & Expiration Year
• Figure 4-3: Tazverik - Price Per Unit & Supply (US$), January'2026
• Figure 4-4: Tazverik - Recommended Initial & Reduced Dose (mg/Twice Daily)
• Figure 4-5: Tazverik - Cost Monthly & Annual Treatment (US$), January'2026
• Figure 4-6: Global - Tazverik Annual Sales (US$ Million), 2022-2025
• Figure 4-7: Global - Tazverik Quarterly Sales (US$ Million), Q1-Q3'2025
• Figure 4-8: Global - Tazverik Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 7-1: EZH2 Targeted Therapy Market - Future Opportunities
• Figure 9-1: EZH2 - Cancer Hallmarks
• Figure 9-2: EZH2 - Canonical vs Non-Canonical Functions
• Figure 9-3: EPZ-IST-001 Phase 2 (NCT05023655) Study - Initiation & Completion Year
• Figure 9-4: 22 041 Phase 1 (NCT04846478) Study - Initiation & Completion Year
• Figure 9-5: EZH-1201 Phase 1 (NCT04241835) Study - Initiation & Completion Year
• Figure 9-6: CHN-PLAGH-BT-055 Phase 1/2 (NCT04407741) Study - Initiation & Completion Year
• Figure 9-7: SPLP-002-21F Phase 1/2 (NCT05467748) Study - Initiation & Completion Year
• Figure 9-8: EZH2 - Overview In Hematologic Malignancies
• Figure 9-9: Hematologic Malignancies - Approved EZH2 Targeting Drugs
• Figure 9-10: 22-07025095 Phase 1 (NCT05934838) Study - Initiation & Completion Year
• Figure 9-11: 23-06026184 Phase 2 (NCT05994235) Study - Initiation & Completion Year
• Figure 9-12: CLIN-60200-452 Phase 2 (NCT06068881) Study - Initiation & Completion Year
• Figure 9-13: NCI-2022-05327 Phase 1 (NCT05627245) Study - Initiation & Completion Year
• Figure 9-14: PTCL-IIT-SHR2554-SHR0302 Phase 2 (NCT06519526) Study - Initiation & Completion Year
• Figure 9-15: EZH2 - Roles Across Immune Cells
• Figure 9-16: EZH2 In Autoimmune & Inflammatory Diseases
• Figure 12-1: EZH2 Targeted Therapy Market - Drivers & Opportunities
• Figure 12-2: EZH2 Targeted Therapy Market - Challenges & Strategic Solutions

List of Tables

• Table 2-1: EZH2 Degraders - Classification
• Table 2-2: EZH2 Gene Silencing - Challenges & Solutions In Clinical Translation

Table 5 -: Ezharmia - Key Points

• Table 6-1: Zeprumetostat - Key Points
• Table 9-1: EZH2 - Involvement In Neurological Diseases